181 related articles for article (PubMed ID: 17288344)
1. [From gene to disease; the haemolytic uraemic syndrome can be caused by mutations in regulating factors of the alternative route of the complement system].
Geelen JM; Klasen IS; van den Heuvel LP; Monnens LA
Ned Tijdschr Geneeskd; 2007 Jan; 151(3):185-8. PubMed ID: 17288344
[TBL] [Abstract][Full Text] [Related]
2. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome.
Sánchez-Corral P; Melgosa M
Br J Haematol; 2010 Sep; 150(5):529-42. PubMed ID: 20629662
[TBL] [Abstract][Full Text] [Related]
4. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.
Fremeaux-Bacchi V; Kemp EJ; Goodship JA; Dragon-Durey MA; Strain L; Loirat C; Deng HW; Goodship TH
J Med Genet; 2005 Nov; 42(11):852-6. PubMed ID: 15784724
[TBL] [Abstract][Full Text] [Related]
5. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.
Kavanagh D; Kemp EJ; Mayland E; Winney RJ; Duffield JS; Warwick G; Richards A; Ward R; Goodship JA; Goodship TH
J Am Soc Nephrol; 2005 Jul; 16(7):2150-5. PubMed ID: 15917334
[TBL] [Abstract][Full Text] [Related]
6. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
Westra D; Volokhina E; van der Heijden E; Vos A; Huigen M; Jansen J; van Kaauwen E; van der Velden T; van de Kar N; van den Heuvel L
Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
[TBL] [Abstract][Full Text] [Related]
7. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
8. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
[TBL] [Abstract][Full Text] [Related]
9. Haemolytic uraemic syndrome.
Kavanagh D; Goodship T
Nephron Clin Pract; 2011; 118(1):c37-42. PubMed ID: 21071971
[TBL] [Abstract][Full Text] [Related]
10. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes.
Dragon-Durey MA; Frémeaux-Bacchi V
Springer Semin Immunopathol; 2005 Nov; 27(3):359-74. PubMed ID: 16189652
[TBL] [Abstract][Full Text] [Related]
11. Atypical haemolytic uraemic syndrome.
Kavanagh D; Goodship TH; Richards A
Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
[TBL] [Abstract][Full Text] [Related]
12. Complement dysfunction in hemolytic uremic syndrome.
Zipfel PF; Skerka C
Curr Opin Rheumatol; 2006 Sep; 18(5):548-55. PubMed ID: 16896298
[TBL] [Abstract][Full Text] [Related]
13. Familial haemolytic uraemic syndrome and an MCP mutation.
Noris M; Brioschi S; Caprioli J; Todeschini M; Bresin E; Porrati F; Gamba S; Remuzzi G;
Lancet; 2003 Nov; 362(9395):1542-7. PubMed ID: 14615110
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
15. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
[TBL] [Abstract][Full Text] [Related]
16. Inherited dysregulation of the complement system.
Goodship T
Bull Mem Acad R Med Belg; 2004; 159(Pt 2):195-8. PubMed ID: 15615093
[TBL] [Abstract][Full Text] [Related]
17. Advances in understanding of pathogenesis of aHUS and HELLP.
Fang CJ; Richards A; Liszewski MK; Kavanagh D; Atkinson JP
Br J Haematol; 2008 Nov; 143(3):336-48. PubMed ID: 18691170
[TBL] [Abstract][Full Text] [Related]
18. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
19. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.
Esparza-Gordillo J; Goicoechea de Jorge E; Buil A; Carreras Berges L; López-Trascasa M; Sánchez-Corral P; Rodríguez de Córdoba S
Hum Mol Genet; 2005 Mar; 14(5):703-12. PubMed ID: 15661753
[TBL] [Abstract][Full Text] [Related]
20. Complement and diseases: defective alternative pathway control results in kidney and eye diseases.
Zipfel PF; Heinen S; Józsi M; Skerka C
Mol Immunol; 2006 Jan; 43(1-2):97-106. PubMed ID: 16026839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
